We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

GENinCode plc (GENI) ORD GBP0.01

Sell:7.50p Buy:8.00p 0 Change: No change
Market closed Prices as at close on 25 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:7.50p
Buy:8.00p
Change: No change
Market closed Prices as at close on 25 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:7.50p
Buy:8.00p
Change: No change
Market closed Prices as at close on 25 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

GENinCode Plc is a United Kingdom-based predictive genetics company. The Company is engaged in the risk assessment, prediction, and prevention of cardiovascular disease (CVD). Its tests include Cardio Incode, Lipid Incode, Sudd Incode, Roca Test, Thrombo and Thrombo Incode Reproductive Health. The Company's product portfolio draws on advanced genomic precision testing using polygenic (multiple genes) technology, molecular testing, genotyping, sequencing, and AI bioinformatics to risk assess patient DNA. Its predictive technology provides patients and physicians with global preventative care and treatment strategies. Its products combine genetic and clinical data to risk-assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease. The Company’s wholly owned subsidiaries include GENinCode S.L.U. and GENinCode U.S. INC.

Contact details

Address:
1 St. Peters Square
OXFORD
OX4 4GP
United Kingdom
Telephone:
+44 (01865) 955847
Website:
https://www.genincode.com/

Important dates

Future events
There are no future events available.
Past events
General meeting 09 January 2024 09/01/24
Interim results 20 September 2023 20/09/23
AGM 30 June 2023 30/06/23
Annual report 08 June 2023 08/06/23
Final results 06 June 2023 06/06/23

General stock information

EPIC:
GENI
ISIN:
GB00BL97B504
Market cap:
£13.71 million
Shares in issue:
176.96 million
Sector:
No specific Industry
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Matthew Walls
    Chief Executive Officer, Executive Director
  • Paul Foulger
    Chief Financial Officer, Executive Director
  • Jordi Gilberte
    Chief Operating Officer, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.